Citadel Advisors’s Grace Therapeutics GRCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $457K | Buy |
98,742
+56,445
| +133% | +$222K | ﹤0.01% | 9518 |
|
|
2025
Q4 | $148K | Buy |
42,297
+15,032
| +55% | +$47.7K | ﹤0.01% | 11335 |
|
|
2025
Q3 | $81K | Sell |
27,265
-7,117
| -21% | -$22.3K | ﹤0.01% | 11967 |
|
|
2025
Q2 | $102K | Sell |
34,382
-4,021
| -10% | -$10.7K | ﹤0.01% | 11333 |
|
|
2025
Q1 | $87.6K | Buy |
38,403
+14,739
| +62% | +$46.4K | ﹤0.01% | 11652 |
|
|
2024
Q4 | $90.2K | Buy |
+23,664
| New | +$81K | ﹤0.01% | 11631 |
|
|
2022
Q4 | – | Sell |
-2,971
| Closed | -$10K | – | 15569 |
|
|
2022
Q3 | $10K | Buy |
+2,971
| New | +$14.6K | ﹤0.01% | 12279 |
|
|
2021
Q4 | – | Sell |
-6,095
| Closed | -$73K | – | 14943 |
|
|
2021
Q3 | $73K | Buy |
6,095
+3,785
| +164% | +$74.5K | ﹤0.01% | 13133 |
|
|
2021
Q2 | $62K | Buy |
+2,310
| New | +$56.3K | ﹤0.01% | 13235 |
|
|
2021
Q1 | – | Sell |
-5,699
| Closed | -$89K | – | 13813 |
|
|
2020
Q4 | $89K | Buy |
+5,699
| New | +$65.8K | ﹤0.01% | 10289 |
|
|
2020
Q3 | – | Sell |
-4,380
| Closed | -$99K | – | 10866 |
|
|
2020
Q2 | $99K | Buy |
4,380
+2,876
| +191% | +$83.9K | ﹤0.01% | 9001 |
|
|
2020
Q1 | $27K | Buy |
1,504
+1,010
| +204% | +$35.8K | ﹤0.01% | 9223 |
|
|
2019
Q4 | $58K | Sell |
494
-42
| -8% | -$4.15K | ﹤0.01% | 8717 |
|
|
2019
Q3 | $49K | Buy |
+536
| New | +$49.6K | ﹤0.01% | 8713 |
|
|
2019
Q1 | – | Sell |
-1,255
| Closed | -$50K | – | 9979 |
|
|
2018
Q4 | $50K | Buy |
+1,255
| New | +$54.7K | ﹤0.01% | 8492 |
|
|
2018
Q3 | – | Sell |
-680
| Closed | -$19K | – | 9788 |
|
|
2018
Q2 | $19K | Buy |
+680
| New | +$26.1K | ﹤0.01% | 8664 |
|
|
2018
Q1 | – | Sell |
-541
| Closed | -$24K | – | 8886 |
|
|
2017
Q4 | $24K | Sell |
541
-81
| -13% | -$5.44K | ﹤0.01% | 7803 |
|
|
2017
Q3 | $43K | Buy |
622
+117
| +23% | +$7.35K | ﹤0.01% | 7216 |
|
|
2017
Q2 | $32K | Buy |
+505
| New | +$31.4K | ﹤0.01% | 7196 |
|
|
2015
Q4 | – | Sell |
-75
| Closed | -$10K | – | 9293 |
|
|
2015
Q3 | $10K | Sell |
75
-57
| -43% | -$9.56K | ﹤0.01% | 8474 |
|
|
2015
Q2 | $20K | Buy |
+132
| New | +$24.5K | ﹤0.01% | 8154 |
|
|
2015
Q1 | – | Sell |
-83
| Closed | -$20K | – | 8919 |
|
|
2014
Q4 | $20K | Buy |
+83
| New | +$20.4K | ﹤0.01% | 7808 |
|
|
2014
Q3 | – | Sell |
-40
| Closed | -$20K | – | 8457 |
|
|
2014
Q2 | $20K | Sell |
40
-152
| -79% | -$72.6K | ﹤0.01% | 7287 |
|
|
2014
Q1 | $106K | Buy |
+192
| New | +$117K | ﹤0.01% | 6144 |
|
Other funds holding GRCE
EP
NCM
VCM
CCM
QC
Citadel Advisors's GRCE Position: Q1 2026 in Review
Citadel Advisors increased its Grace Therapeutics (GRCE) stake by 133% in Q1 2026, buying an estimated $222K and bringing the position to 98,742 shares worth $457K. The position accounts for ﹤0.01% of the portfolio, ranked #9518.
Citadel Advisors first reported a position in GRCE in Q1 2014 and has held it in 24 quarters since. 34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.
- Citadel Advisors held 98,742 shares of Grace Therapeutics worth $457K as of Q1 2026.
- Citadel Advisors bought 56,445 Grace Therapeutics shares in Q1 2026, an estimated $222K.
- Grace Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9518 holding.
- Citadel Advisors first reported a position in Grace Therapeutics in Q1 2014 and has held it in 24 quarters since.
- 34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.